A.M.I.
  • Headquarters: Feldkirch, Austria
  • Sector: MedTech
  • Investment role: Lead investor (majority shareholder)
  • Responsible: Michel Galeazzi
  • Current Investment

A.M.I. develops, manufactures and distributes minimally-invasive products and treatment methods for surgical applications. The Austrian company stands for innovation and quality and is a leading player in the fields of coloproctology, urogynaecology and urology.

2022

Year of investment

125

Employees

20m

Revenue (in EUR, 2023)

Strategy & key initiatives

  • Refine product portfolio to focus on key indications
  • Introduce Strategic Advisory Board and install a governance ready for growth
  • Hire Co-Managing Director and supporting the build-up of the team, including establishing the A.M.I. Academy for training and development of A.M.I. staff
  • Improve operations in procurement, production and distribution as well as R&D
  • Maintaining and fostering the MedTech regulatory portfolio

Evoco Team